$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000154422716000016 Filed on November 03, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$120.0K	$197.0K	$75.00K
YoY Change	-25.0%	162.67%
Cost Of Revenue	$1.430M	$1.559M	$940.0K
YoY Change	23.28%	65.85%
Gross Profit	-$1.310M	-$1.362M	-$865.0K
YoY Change	31.0%	57.46%
Gross Profit Margin	-1091.67%	-691.37%	-1153.33%
Selling, General & Admin	$10.95M	$12.61M	$12.91M
YoY Change	-24.85%	-2.3%	82.49%
% of Gross Profit
Research & Development	$4.710M	$4.990M	$3.998M
YoY Change	0.86%	24.81%	-24.92%
% of Gross Profit
Depreciation & Amortization	$590.0K	$600.0K	$300.0K
YoY Change	9.26%	100.0%	200.0%
% of Gross Profit
Operating Expenses	$15.66M	$19.16M	$17.85M
YoY Change	-18.61%	7.36%	43.94%
Operating Profit	-$16.97M	-$18.96M	-$17.77M
YoY Change	-16.16%	6.71%	43.33%
Interest Expense	-$210.0K	-$200.0K	-$180.0K
YoY Change	-12.5%	11.11%	-67.27%
% of Operating Profit
Other Income/Expense, Net	-$80.00K	-$33.00K	$25.00K
YoY Change	60.0%	-232.0%	4.17%
Pretax Income	-$22.66M	-$19.20M	-$17.92M
YoY Change	10.38%	7.13%	38.72%
Income Tax	-$20.00K	$92.00K	$0.00
% Of Pretax Income
Net Earnings	-$22.64M	-$19.29M	-$17.92M
YoY Change	9.9%	7.64%	38.68%
Net Earnings / Revenue	-18866.67%	-9792.39%	-23896.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$141.50	-$120.60	-$149.30
COMMON SHARES
Basic Shares Outstanding	35.61M shares	35.56M shares	27.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$114.4M	$131.0M	$141.7M
YoY Change	-9.71%	-7.55%	96.26%
Cash & Equivalents	$43.93M	$50.48M	$50.84M
Short-Term Investments	$70.50M	$80.50M	$90.80M
Other Short-Term Assets	$2.100M	$2.500M	$3.600M
YoY Change	-34.38%	-30.56%	157.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$116.4M	$133.5M	$145.3M
YoY Change	-10.33%	-8.17%	97.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.572M	$8.047M	$6.717M
YoY Change	-32.97%	19.8%	116.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$65.00K	$435.0K	$241.0K
YoY Change		80.5%	-59.83%
Other Assets	$23.00K	$23.00K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$6.099M	$8.944M	$7.485M
YoY Change	-30.31%	19.49%	91.92%
TOTAL ASSETS
Total Short-Term Assets	$116.4M	$133.5M	$145.3M
Total Long-Term Assets	$6.099M	$8.944M	$7.485M
Total Assets	$122.5M	$142.4M	$152.8M
YoY Change	-11.59%	-6.81%	97.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.183M	$2.770M	$4.156M
YoY Change	-34.87%	-33.35%	38.53%
Accrued Expenses	$11.03M	$8.500M	$5.700M
YoY Change	39.73%	49.12%	-1.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.21M	$11.27M	$9.863M
YoY Change	17.49%	14.22%	12.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.116M	$1.300M	$358.0K
YoY Change	114.62%	263.13%	258.0%
Total Long-Term Liabilities	$1.116M	$1.300M	$358.0K
YoY Change	114.62%	263.13%	258.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.21M	$11.27M	$9.863M
Total Long-Term Liabilities	$1.116M	$1.300M	$358.0K
Total Liabilities	$14.33M	$12.52M	$10.22M
YoY Change	21.78%	22.5%	14.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$250.2M	-$227.5M	-$147.3M
YoY Change	48.99%	54.45%
Common Stock	$36.00K	$36.00K	$27.00K
YoY Change	33.33%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$108.2M	$129.9M	$142.6M
YoY Change
Total Liabilities & Shareholders Equity	$122.5M	$142.4M	$152.8M
YoY Change	-11.59%	-6.81%	97.17%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$22.64M	-$19.29M	-$17.92M
YoY Change	9.9%	7.64%	38.68%
Depreciation, Depletion And Amortization	$590.0K	$600.0K	$300.0K
YoY Change	9.26%	100.0%	200.0%
Cash From Operating Activities	-$14.96M	-$15.44M	-$12.52M
YoY Change	32.16%	23.32%	46.78%
INVESTING ACTIVITIES
Capital Expenditures	$1.540M	$180.0K	$1.170M
YoY Change	-47.08%	-84.62%	277.42%
Acquisitions
YoY Change
Other Investing Activities	$9.970M	-$29.90M	-$5.780M
YoY Change	48.14%	417.3%	-228.16%
Cash From Investing Activities	$8.420M	-$30.07M	-$6.950M
YoY Change	120.42%	332.66%	-265.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	100.0K	80.00K
YoY Change	-91.67%	25.0%	-188.89%
NET CHANGE
Cash From Operating Activities	-14.96M	-15.44M	-12.52M
Cash From Investing Activities	8.420M	-30.07M	-6.950M
Cash From Financing Activities	-10.00K	100.0K	80.00K
Net Change In Cash	-6.550M	-45.41M	-19.39M
YoY Change	-14.04%	134.19%	338.69%
FREE CASH FLOW
Cash From Operating Activities	-$14.96M	-$15.44M	-$12.52M
Capital Expenditures	$1.540M	$180.0K	$1.170M
Free Cash Flow	-$16.50M	-$15.62M	-$13.69M
YoY Change	15.95%	14.1%	54.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35608386	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2016Q3	ovas	Allocated Share Based Compensation Expense Reversed AllocatedShareBasedCompensationExpenseReversed	100000	USD
	ovas	Allocated Share Based Compensation Expense Reversed AllocatedShareBasedCompensationExpenseReversed	2200000	USD
CY2015Q1	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	345000	shares
CY2016Q2	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	1072500	shares
CY2016Q3	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2016Q3	ovas	Potential Treatments In Development PotentialTreatmentsInDevelopment	2	treatment
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	1445000	USD
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	221000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3352000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2770000	USD
CY2015Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7891000	USD
CY2016Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8496000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2420000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4027000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	294910000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	357397000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	792000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	607000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4765000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5757000	shares
CY2015Q4	us-gaap	Assets Assets	138613000	USD
CY2016Q3	us-gaap	Assets Assets	142398000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	129861000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	133454000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126662000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	170000	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	130995000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126832000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	131017000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17900000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52664000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	81400000	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	44900000	USD
CY2016Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	2600000	USD
CY2015Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	43	security
CY2016Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	18	security
CY2016Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	20	security
CY2016Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	2	security
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6414000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50842000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50480000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	131000000	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27296747	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35607059	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27296747	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35607059	shares
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19322000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59469000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	940000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1091000	USD
CY2016Q3	us-gaap	Cost Of Revenue CostOfRevenue	1559000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3968000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	520000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1255000	USD
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	748000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	USD
CY2016Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1645000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1600000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.95
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2015Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2016Q3	us-gaap	Equity Method Investments EquityMethodInvestments	435000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17922000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52618000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19199000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-59400000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	142398000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11243000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11266000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	44428000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	162000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	497000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	116000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	11763000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	12521000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138613000	USD
CY2015Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-316000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1176000	USD
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-364000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1171000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	217000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-139000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-639000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1449000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1184000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1894000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-543000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	439000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-197000	USD
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	141000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	286000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	7256000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125508000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54155000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42113000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38967000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46765000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-17922000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52618000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-19291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-59617000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	17847000	USD
	us-gaap	Operating Expenses OperatingExpenses	51879000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	19161000	USD
	us-gaap	Operating Expenses OperatingExpenses	59176000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17772000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51759000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18964000	USD
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3002000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2459000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58644000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-46000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	148000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-82000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	3300000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1800000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1750000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2323000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1045000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	82072000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	65633000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124100000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124063000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53934000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	41104000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	45008000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3117000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23089000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10733000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12074000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8313000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8047000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3998000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13766000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4990000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16932000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	129877000	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27267000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27020000	shares
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	197000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167917000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-227534000	USD
CY2015Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	120000	USD
CY2016Q3	us-gaap	Revenues Revenues	197000	USD
	us-gaap	Revenues Revenues	532000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12909000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37022000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12612000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38276000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14417000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8225000	USD
CY2016Q2	us-gaap	Share Price SharePrice	7
CY2015Q1	us-gaap	Share Price SharePrice	50
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	83438000	USD
CY2016Q3	us-gaap	Short Term Investments ShortTermInvestments	80515000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2645000	shares
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8222500	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	126850000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35568000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30985000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-16-000016-index-headers.html	Edgar Link	pending
0001544227-16-000016-index.html	Edgar Link	pending
0001544227-16-000016.txt	Edgar Link	pending
0001544227-16-000016-xbrl.zip	Edgar Link	pending
ex102.htm	Edgar Link	pending
ex102image1.gif	Edgar Link	pending
ex103mgh.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20160930.xml	Edgar Link	completed
ovas-20160930.xsd	Edgar Link	pending
ovas-20160930x10q.htm	Edgar Link	pending
ovas-20160930xex311.htm	Edgar Link	pending
ovas-20160930xex312.htm	Edgar Link	pending
ovas-20160930xex321.htm	Edgar Link	pending
ovas-20160930xex322.htm	Edgar Link	pending
ovas-20160930_cal.xml	Edgar Link	unprocessable
ovas-20160930_def.xml	Edgar Link	unprocessable
ovas-20160930_lab.xml	Edgar Link	unprocessable
ovas-20160930_pre.xml	Edgar Link	unprocessable
ovasamendmentno6tomgh_image1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2016 Q4 Form 10-Q Financial Statement

#000154422716000016 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2016 Q4 Form 10-Q Financial Statement

#000154422716000016 Filed on November 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst